Clinical trials of mAbs grown more than 100 percent


Clinical trials of monoclonal antibodies (mAb), have grown 115% globally in the ten year period 2007–2016 according to GlobalData, a leading data and analytics company

Clinical trials of mAbs grown more than 100 percent

The company tracks clinical trials activity across the world and has identified 5273 industry mAb clinical trials between 1 January 2007 and 31 December 2016.

In 2015, the most prominent increase in new clinical trials of mAbs, 26%, occurred.

A small number of Phase 0, Phase I/II, Phase II/III and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Overall, Phase II trials outnumbered all other trials by contributing between 31% and 46% across the period.

A spokesperson from the GlobalData Pharma analyst team, said: “The share of Phase I trials started at 18% in 2007 and increased to 27% by 2016. Phase III trials’ contribution remained flat at an average of 24% across the 10 year period, whereas Phase IV trials decreased in share from 13% to 12% in the first and last years, respectively.”

Sign up for your free email newsletter